Department of Ophthalmology, VU University Medical Center, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
Department of Psychology, Health & Technology, University of Twente, Enschede, The Netherlands.
Invest Ophthalmol Vis Sci. 2018 Apr 1;59(5):1916-1923. doi: 10.1167/iovs.17-23224.
To investigate the burden of visual impairment and comorbid fatigue in terms of impact on daily life, by estimating societal costs (direct medical costs and indirect non-health care costs) accrued by these conditions.
This cost-of-illness study was performed from a societal perspective. Cross-sectional data of visually impaired adults and normally sighted adults were collected through structured telephone interviews and online surveys, respectively. Primary outcomes were fatigue severity (FAS), impact of fatigue on daily life (MFIS), and total societal costs. Cost differences between participants with and without vision loss, and between participants with and without fatigue, were examined by (adjusted) multivariate regression analyses, including bootstrapped confidence intervals.
Severe fatigue (FAS ≥ 22) and high fatigue impact (MFIS ≥ 38) was present in 57% and 40% of participants with vision loss (n = 247), respectively, compared to 22% (adjusted odds ratio [OR] 4.6; 95% confidence interval [CI] [2.7, 7.6]) and 11% (adjusted OR 4.8; 95% CI [2.7, 8.7]) in those with normal sight (n = 233). A significant interaction was found between visual impairment and high fatigue impact for total societal costs (€449; 95% CI [33, 1017]). High fatigue impact was associated with significantly increased societal costs for participants with visual impairment (mean difference €461; 95% CI [126, 797]), but this effect was not observed for participants with normal sight (€12; 95% CI [-527, 550]).
Visual impairment is associated with an increased prevalence of high fatigue impact that largely determines the economic burden of visual impairment. The substantial costs of visual impairment and comorbid fatigue emphasize the need for patient-centered interventions aimed at decreasing its impact.
通过估算这些疾病带来的社会成本(直接医疗成本和间接非医疗保健成本),研究视力障碍和合并疲劳对日常生活的负担,以评估其影响。
本项疾病成本研究从社会角度进行。通过结构电话访谈和在线调查分别收集了视力障碍成年人和正常视力成年人的横断面数据。主要结局指标为疲劳严重程度(FAS)、疲劳对日常生活的影响(MFIS)和总社会成本。通过(调整后的)多元回归分析,包括引导置信区间,检验有和无视力损失的参与者以及有和无疲劳的参与者之间的成本差异。
视力障碍者(n = 247)中,严重疲劳(FAS≥22)和高疲劳影响(MFIS≥38)的发生率分别为 57%和 40%,而正常视力者(n = 233)中分别为 22%(调整后的优势比[OR]4.6;95%置信区间[CI]2.7,7.6)和 11%(调整后的 OR 4.8;95% CI 2.7,8.7)。视力障碍和高疲劳影响对总社会成本存在显著的交互作用(€449;95% CI [33,1017])。高疲劳影响与视力障碍患者的社会成本显著增加相关(平均差异€461;95% CI [126,797]),但在正常视力患者中未观察到这种影响(€12;95% CI [-527,550])。
视力障碍与高疲劳影响的发生率增加有关,这在很大程度上决定了视力障碍的经济负担。视力障碍和合并疲劳的大量成本强调了需要采取以患者为中心的干预措施,以降低其影响。